ReviewMolecular therapy. Methods & clinical development2016
Production and clinical development of nanoparticles for gene delivery.
Review in Molecular therapy. Methods & clinical development, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 107 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
107 citing papers in PubMed, 264 citations in OpenAlex.
- Mouth rinses efficacy on salivary SARS-CoV-2 viral load: A randomized clinical trial.Journal of medical virology · 2023Trial
- From Cell-Derived Vesicles to Hybrid Nanovectors: Biological Membranes as Functional Blueprints for Gene Delivery.Advanced healthcare materials · 2026Review
- Genomic Deletion of P-Glycoprotein from Gliomas Via the Focused Ultrasound-Delivery of a Duplex CRISPR Cas9 Ribonucleoprotein System.Cell biomaterials · 2026Article
- From mechanism to medicine: CRISPR‒Cas9 delivery strategies, therapeutic applications and translation challenges.Discover nano · 2026Review
- Cationic lipid-based nanoparticles for therapeutic delivery in cancer treatment: physicochemical characteristics, therapeutic cargos, and clinical potential.Applied microscopy · 2026Review
- Genetic medicines for epilepsy: unlocking new avenues for seizure control.Frontiers in bioengineering and biotechnology · 2026Review
- Implantation of engineered adipocytes suppresses tumor progression in cancer models.Nature biotechnology · 2025Article
- Nanoparticle technologies in precision oncology and personalized vaccine development: Challenges and advances.International journal of pharmaceutics: X · 2025Review
- Nanoparticle‑based delivery systems for targeted therapy in brain tumors: Progress, challenges and perspectives (Review).International journal of oncology · 2025Review
- Synthetic Polymers for Drug, Gene, and Vaccine Delivery.Polymer science & technology (Washington, D.C.) · 2025Review
- Innovative PEGylated chitosan nanocarriers for co-delivery of doxorubicin and CpG in breast cancer therapy: Preparation, characterization, and immunotherapeutic potential.Medical oncology (Northwood, London, England) · 2025Article
- Current Landscape and Future Directions in Cancer Immunotherapy: Therapies, Trials, and Challenges.Cancers · 2025Review
- Double-targeted liposomes coated with matrix metallopeptidase-2-responsive polypeptide nanogel for chemotherapy and enhanced immunotherapy against cervical cancer.Materials today. Bio · 2025Article
- Fibroin-Hybrid Systems: Current Advances in Biomedical Applications.Molecules (Basel, Switzerland) · 2025Review
- Recent Trends in Biomedical Applications of CuInternational journal of nanomedicine · 2025Review
- Advances in nanomaterial-mediated CRISPR/Cas delivery: from lipid nanoparticles to vesicle-derived systems.Frontiers in bioengineering and biotechnology · 2025Review
- Unravelling the Role of Tyrosine and Tyrosine Hydroxylase in Parkinson's Disease: Exploring Nanoparticle-based Gene Therapies.CNS & neurological disorders drug targets · 2025Review
- Ultrasound nanodroplets loaded with Siglec-G siRNA and FeJournal of nanobiotechnology · 2024Article
- Exploring the innovative application of cerium oxide nanoparticles for addressing oxidative stress in ovarian tissue regeneration.Journal of ovarian research · 2024Review
- Biodegradable silica nanoparticles for efficient linear DNA gene delivery.Drug delivery · 2024Article
47 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gene therapy is a promising strategy for specific treatment of numerous gene-associated human diseases by intentionally altering the gene expression in pathological cells. A successful clinical application of gene-based therapy depends on an efficient gene delivery system. Many efforts have been attempted to improve the safety and efficiency of gene-based therapies. Nanoparticles have been proved to be the most promising vehicles for clinical gene therapy due to their tunable size, shape, surface, and biological behaviors. In this review, the clinical development of nanoparticles for gene delivery will be particularly highlighted. Several promising candidates, which are closest to clinical applications, will be briefly reviewed. Then, the recent developments of nanoparticles for clinical gene therapy will be identified and summarized. Finally, the development of nanoparticles for clinical gene delivery in future will be prospected.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.